FDA approves new diabetes drug

Saturday 19 November 2022
Country

United States

The US Food and Drug Administration has approved a new treatment for Type 1 diabetes that can delay the onset of stage 3 of the disease. It is the first therapy for people with the disease who are at risk of having their condition worsen. The drug, Tzield (teplizumab), is an anti-CD3-directed antibody for intravenous use that has been approved for adult and paediatric patients aged eight years and older with stage 2 Type 1 diabetes. The developer is Provention Bio Inc of the US.